Washington: The U.S. Senate voted 77-20 on Dec 17 to advance the fiscal 2026 National Defense Authorization Act, authorizing roughly US$901 billion, a 4% troop pay raise, and measures to bolster European security while restricting certain China-linked biotech and outbound investments; President Trump signed the law this week. Based on 6 articles reviewed and supporting research.
This 60-second summary was prepared by the JQJO editorial team after reviewing 4 original reports from The Straits Times, CNA, Nikkei Asia and Social News XYZ.
U.S. defense contractors, NATO planners, allied militaries, and India (per provisions) stand to gain increased procurement, cooperative opportunities, and strategic support funded by the NDAA.
Targeted Chinese biotech firms and sectors face new restrictions, while U.S. taxpayers and budget hawks will shoulder higher defence spending obligations.
After reading and researching latest news.... The 2026 NDAA cleared both chambers with 77-20 Senate support, authorizes roughly US$901 billion, includes a 4% troop pay raise, China biotech and outbound investment restrictions, measures to bolster European security, and provisions expanding engagement with India and the Quad, reported by multiple outlets.
No left-leaning sources found for this story.
Comments